Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Blood (2024) 144 (22): 2360–2363.

https://doi.org/10.1182/blood.2024025834

Published: 2024

Includes: Supplemental data

Journal Articles

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea

Blood (2024) 144 (21): 2211–2222.

https://doi.org/10.1182/blood.2024024944

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Naseem S. Esteghamat, Joseph M Tuscano, Brian A. Jonas, Aaron S. Rosenberg, Rasmus T. Hoeg, Francisco Andres Socola, Brian Fury, Jordan Pavlic, Geralyn Annett, Jan A. Nolta, Mehrdad Abedi

Blood (2024) 144 (Supplement 1): 2085.

https://doi.org/10.1182/blood-2024-206680

Published: 2024

Journal Articles

Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in m IDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial

Jorge E. Cortes, Gail J. Roboz, Justin M. Watts, Maria R. Baer, Brian A. Jonas, Gary J. Schiller, Karen Yee, Brent Ferrell, Jay Yang, Eunice S. Wang, William Blum, Alice Mims

Blood (2024) 144 (Supplement 1): 2886.

https://doi.org/10.1182/blood-2024-201710

Published: 2024

Journal Articles

Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

Brian A. Jonas, Zarir E. Karanjawala, Laura Molnar, Ashley Linh Dang-Chu, Mehrdad Abedi, Naseem S. Esteghamat, Aaron S. Rosenberg, Francisco Andres Socola, Lihong Qi, Joseph M. Tuscano

Blood (2024) 144 (Supplement 1): 1503.

https://doi.org/10.1182/blood-2024-212328

Published: 2024

Journal Articles

The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Blood (2024) 144 (Supplement 1): 4184.

https://doi.org/10.1182/blood-2024-205812

Published: 2024

Journal Articles

Time to Response and Overall Survival in Patients with m IDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib

Eunice S. Wang, Jorge E. Cortes, Justin M. Watts, Brian A. Jonas, Andrew H Wei, Jay Yang, Joseph G Jurcic, Gail J. Roboz, Karen Seiter, Alice Mims, Karen Yee, Brent Ferrell, Shira N. Dinner, William B. Donnellan, William Blum, Francois Di Trapani, Hua Tian, Stephane De Botton

Blood (2024) 144 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2024-198504

Published: 2024

Journal Articles

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Blood (2024) 144 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2024-206538

Published: 2024

Journal Articles

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Blood (2024) 144 (Supplement 1): 733.

https://doi.org/10.1182/blood-2024-209097

Published: 2024

Journal Articles

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Blood (2024) 144 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2024-200397

Published: 2024

Journal Articles

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Jorge Cortes, Joseph Jurcic, Maria R. Baer, William Blum, P. Brent Ferrell, Jr., Brian A. Jonas, Sangmin Lee, Alice Mims, Shyam Ajay Patel, Gary J. Schiller, Jay Yang, Justin M. Watts

Blood (2023) 142 (Supplement 1): 2888.

https://doi.org/10.1182/blood-2023-187861

Published: 2023

Journal Articles

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, Brian A. Jonas, Radovan Vrhovac, Pau Montesinos, Jacqueline S. Garcia, David Rizzieri, Michael J Thirman, Stanley Kotey, Jalaja Potluri, Mazaher Dhalla, Vinod Pullarkat

Blood (2023) 142 (Supplement 1): 2886.

https://doi.org/10.1182/blood-2023-182045

Published: 2023

Journal Articles

Preliminary Results from a Phase 1b/2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine in Patients (Pts) with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)

Brian A. Jonas, Karen Yee, Alice Mims, Paul B. Koller, Joseph Brandwein, Gail J. Roboz, Glenn Michelson, Linh Nguyen, Mark R Bray, Emily Roberts-Thomson, Roger Sidhu, Gautam Borthakur

Blood (2023) 142 (Supplement 1): 4294.

https://doi.org/10.1182/blood-2023-182027

Published: 2023

Journal Articles

Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Naval Daver, Kyoo Hyung Lee, Yunsuk Choi, Brian A. Jonas, Martha Arellano, Paul B. Koller, Chul W. Jung, Sang Kyun Sohn, Amir T. Fathi, Jeong-Ok Lee, Sung-Soo Yoon, Justin M. Watts, Pankit Vachhani, Ho-Jin Shin, Jia Hu, Ranjeet Sinha, Nawazish Khan, William G. Rice, Rafael Bejar

Blood (2023) 142 (Supplement 1): 162.

https://doi.org/10.1182/blood-2023-182296

Published: 2023

Journal Articles

A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy

Blood (2023) 142 (Supplement 1): 5946.

https://doi.org/10.1182/blood-2023-184344

Published: 2023

Journal Articles

Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia

Eunice S. Wang, Brian A. Jonas, Justin M. Watts, Joseph Jurcic, P. Brent Ferrell, Jr., Shira N. Dinner, Jay Yang, Karen Seiter, Alice Mims, William B. Donnellan, William Blum, Jorge Cortes

Blood (2023) 142 (Supplement 1): 6047.

https://doi.org/10.1182/blood-2023-187584

Published: 2023

Journal Articles

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Blood (2023) 141 (15): 1884–1888.

https://doi.org/10.1182/blood.2022017686

Published: 2023

Includes: Supplemental data

Journal Articles

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Blood (2023) 141 (11): 1265–1276.

https://doi.org/10.1182/blood.2022016362

Published: 2023

Includes: Supplemental data

Journal Articles

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Keith W. Pratz, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Walter Fiedler, Kazuhito Yamamoto, Jianxiang Wang, Sung-Soo Yoon, Ofir Wolach, Jun-Ho Jang, Su-Peng Yeh, Grace Ku, Ying Zhou, Brenda Chyla, Jalaja Potluri, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 529–531.

https://doi.org/10.1182/blood-2022-158518

Published: 2022

Journal Articles

Assessing Time to Diagnosis, End-Organ Damage and Treatment Response in Young Newly Diagnosed Multiple Myeloma Patients

Michelle A. Quan, Kwan-Keat Ang, Joseph M Tuscano, Mehrdad Abedi, Brian A. Jonas, Naseem S Esteghamat, Jeanna L Welborn, Paul R. Kaesberg, Aaron S Rosenberg

Blood (2022) 140 (Supplement 1): 7203–7205.

https://doi.org/10.1182/blood-2022-162959

Published: 2022

NARROW

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in m IDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial

Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Time to Response and Overall Survival in Patients with m IDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy

Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Assessing Time to Diagnosis, End-Organ Damage and Treatment Response in Young Newly Diagnosed Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only